Last reviewed · How we verify
Amisulpride IV Treatment
Amisulpride IV Treatment is a Atypical antipsychotic Small molecule drug developed by Benaroya Research Institute. It is currently in Phase 3 development for Acute psychosis or schizophrenia (IV formulation for rapid symptom management).
Amisulpride is a selective dopamine D2/D3 receptor antagonist that blocks dopamine signaling in the brain.
Amisulpride is a selective dopamine D2/D3 receptor antagonist that blocks dopamine signaling in the brain. Used for Acute psychosis or schizophrenia (IV formulation for rapid symptom management).
At a glance
| Generic name | Amisulpride IV Treatment |
|---|---|
| Sponsor | Benaroya Research Institute |
| Drug class | Atypical antipsychotic |
| Target | Dopamine D2 receptor, Dopamine D3 receptor |
| Modality | Small molecule |
| Therapeutic area | Psychiatry |
| Phase | Phase 3 |
Mechanism of action
Amisulpride preferentially antagonizes dopamine receptors in the mesolimbic and mesocortical pathways at low doses, and in the nigrostriatal pathway at higher doses. This dopamine blockade is thought to reduce psychotic symptoms and improve mood regulation. The IV formulation allows for rapid onset of action compared to oral administration.
Approved indications
- Acute psychosis or schizophrenia (IV formulation for rapid symptom management)
Common side effects
- Akathisia
- Parkinsonism
- Hyperprolactinemia
- Weight gain
- Sedation
- Orthostatic hypotension
Key clinical trials
- Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings (EARLY_PHASE1)
- Study of Intravenous Amisulpride for Prophylaxis of Post-operative Nausea and Vomiting (PONV) in Pediatric Patients (PHASE2, PHASE3)
- A Pilot Study to Evaluate Barhemsys for the Prevention of Postoperative Nausea and Vomiting in the Bariatric Surgery Population (PHASE3)
- A Comparison of the Efficacy of Amisulpride and Placebo in the Prevention of PONV in Patients at Moderate-to-high Risk of PONV. (PHASE3)
- Post Operative Nausea and Vomiting (PONV) Rescue Outcomes After Amisulpride Treatment
- US Phase III Study of APD421 in PONV (PHASE3)
- Study of APD421 as PONV Treatment (Prior Prophylaxis) (PHASE3)
- Study of APD421 as PONV Treatment (no Prior Prophylaxis) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Amisulpride IV Treatment CI brief — competitive landscape report
- Amisulpride IV Treatment updates RSS · CI watch RSS
- Benaroya Research Institute portfolio CI
Frequently asked questions about Amisulpride IV Treatment
What is Amisulpride IV Treatment?
How does Amisulpride IV Treatment work?
What is Amisulpride IV Treatment used for?
Who makes Amisulpride IV Treatment?
What drug class is Amisulpride IV Treatment in?
What development phase is Amisulpride IV Treatment in?
What are the side effects of Amisulpride IV Treatment?
What does Amisulpride IV Treatment target?
Related
- Drug class: All Atypical antipsychotic drugs
- Target: All drugs targeting Dopamine D2 receptor, Dopamine D3 receptor
- Manufacturer: Benaroya Research Institute — full pipeline
- Therapeutic area: All drugs in Psychiatry
- Indication: Drugs for Acute psychosis or schizophrenia (IV formulation for rapid symptom management)
- Compare: Amisulpride IV Treatment vs similar drugs
- Pricing: Amisulpride IV Treatment cost, discount & access